Low Float (Nasdaq: CTXR) Is Generating Revenue For The First Time (5 Potential Catalysts)

Catch our latest Nasdaq profile?

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Low Float (Nasdaq: CTXR) Is Generating Revenue For The First Time (5 Potential Catalysts) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* March 5th Greetings, Friend! Catch our latest Nasdaq profile?  Surging to a high of $3.19 Wednesday from Tuesday's $2.54 close, that breakout idea popped approx. 25% short term. But, now it's time to look forward... Breakthroughs in oncology and infectious disease are reshaping the biopharmaceutical landscape as innovators push to meet some of medicine’s most pressing challenges. Amid this momentum, a handful of companies are redefining treatment standards with pioneering therapies that set a new bar for patient care. Among them is one organization driving advances in immunotherapy for rare cancers and developing distinctive treatments aimed at improving supportive cancer care—areas of intense clinical need. And with a global $1.04Bn CTLC market up for grabs, this under-the-radar profile could start earning some serious buzz. Why? How about recent commercialization/first generated revenue announcements. Now, mix in a low float, a strong analyst target, and key chart positioning, and it becomes easier to understand why this Nasdaq profile is topping our watchlist: Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In December 2025, a subsidiary of Citius Pharmaceuticals launched LYMPHIR™, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharmaceuticals' Novel Targeted Oncology Asset - LYMPHIR™ LYMPHIR™ (denileukin diftitox-cxdl), Citius' targeted immune therapy for adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) is now approved by the FDA. CTXR's team’s extensive experience in the pharmaceutical industry allows them to identify compelling opp's and develop assets that have unique commercial advantages and differentiated upside potential. By deploying capital thoughtfully, they believe their activities will provide patients and caregivers with improved treatment options and deliver long-term sustainable value to shareholders. Strategic Significance of the LYMPHIR™ Launch for Citius Pharmaceuticals The commercial launch of LYMPHIR™ marks a pivotal moment for Citius Pharmaceuticals, signaling its evolution from a development-stage organization to a fully integrated, revenue-generating biopharmaceutical company. This achievement reflects years of coordinated research, regulatory preparation, and commercial planning, now culminating in market entry. With LYMPHIR’s approval and availability, the company expands its capabilities beyond drug development into commercialization, a critical step toward sustainable growth and shareholder value creation. Addressing a Long-Standing Clinical Gap As the first FDA-approved systemic therapy for cutaneous T-cell lymphoma (CTCL) in over seven years, LYMPHIR represents a major advance for patients facing relapsed or refractory disease. Its unique IL-2 receptor-directed design and demonstrated efficacy — including a median time to response of 1.4 months — position it as an essential therapeutic option for those suffering from CTCL’s debilitating symptoms. The absence of cumulative toxicity further differentiates the therapy, reinforcing Citius Pharmaceuticals’ mission to deliver meaningful, safe, and effective treatments for underserved conditions. Strengthening Commercial and Market Position The U.S. CTCL market, estimated at more than $400Mn annually, provides an attractive and scalable opp. for Citius Pharmaceuticals’ first marketed product. The National Comprehensive Cancer Network (NCCN) Guidelines® inclusion and the assignment of a permanent J-code (J9161) streamline the reimbursement process and support adoption among oncologists and treatment centers nationwide. With strong foundations in payer access, field engagement, and medical education initiatives, the company is well positioned to drive uptake and brand equity in this specialized market. Expanding Global and Strategic Horizons While initial efforts focus on U.S. commercialization, the LYMPHIR launch also enables Citius Pharmaceuticals to extend its footprint internationally. Through targeted development and distribution strategies, the company aims to leverage emerging partnerships and explore new market opp's beyond the United States. These activities not only broaden therapeutic access but also diversify revenue potential and support long-term corporate resilience. A Defining Milestone for Growth The introduction of LYMPHIR is more than a single product launch — it is a statement of Citius Pharmaceuticals’ strategic maturity and commitment to advancing medical innovation in rare diseases. By successfully bridging scientific development and market execution, the company strengthens its foundation for future growth and fulfills its promise of improving outcomes for patients with limited treatment options. Opp's For Growth Beyond Cutaneous T-cell Lymphoma (CTCL) University of Pittsburgh: an investigator-initiated trial is underway to evaluate LYMPHIR for potential use as an immunooncology therapy in combination with KEYTRUDA® in patients with recurrent or metastatic solid tumors (NCT05200559). Encouraging preliminary results of interim analysis: 15 evaluable patients showed 27% ORR; 33% Clinical Benefit Rate; median Progression Free Survival of 57 weeks (for patients that achieved a clinical benefit) The data supports further evaluation of this combination across a broader range of solid tumor types Phase 1 Preliminary study data (n=25) anticipated Q1 2026 University of Minnesota: LYMPHIR in combination with CAR T therapies (NCT04855253). Phase 1 study to evaluate the potential benefit of LYMPHIR given prior to CAR T therapy in patients with high risk relapsed/refractory B-cell lymphomas Preliminary study results anticipated Q1 2026 Logical label expansion potential in PTCL where there is a high unmet need and no curative therapies. 1. KEYTRUDA is a registered trademark of Merck & Co., Inc. KYMRIAH is a registered trademark of Novartis Pharmaceuticals Corporation. Grab Sources Here: CTXR Presentation. CTXR Website. ----- 5 Critical Potential Catalysts To Consider - Key (Nasdaq: CTXR) Details There are 5 potential catalysts that could attract attention to CTXR and should be looked at understood closely. Here's what to know: #1. Citius Pharmaceuticals, Inc. Secures $3.8Mn through New Jersey Economic Development Program. Citius Pharmaceuticals secured $3.8Mn in non-dilutive funding through New Jersey’s Economic Development Authority under the Technology Business Tax Certificate Transfer (NOL) Program. This strategic infusion enhances financial flexibility without shareholder dilution, allowing Citius to advance its commercial launch of LYMPHIR™ and progress its late-stage development programs. Company CFO, Jaime Bartushak, highlighted the Company’s disciplined capital use to build long-term shareholder value. The funding underscores Citius’s financial stability and commitment to developing critical-care therapies that improve patient outcomes while supporting sustainable corporate growth. #2. A Limited Float Could Amplify Market Volatility Potential. Market watchers may note that CTXR’s float is on the fairly low side. Based on data from Yahoo Finance, the company’s float is approximately 21.88Mn shares. Why does this matter? A low float can often translate to greater volatility potential. With great volatility potential comes the need for watching CTXR with a very close eye. #3. Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™. Citius Pharmaceuticals reported its first-ever revenue of $3.9Mn following the successful December 2025 launch of LYMPHIR™, marking a transformative step from development to commercialization. Company CEO, Leonard Mazur, credited the achievement to years of focused execution and innovation benefiting patients with cutaneous T-cell lymphoma. With momentum building, Citius plans to expand patient access through a technology-driven platform and explore international growth. The company’s disciplined financial management and advancing pipeline, including Mino-Lok and Halo-Lido, reinforce its long-term commitment to innovation, patient care, and shareholder value creation. #4. CTXR Closed Above 4 Key Technical Chart Support Levels On Wednesday. At 4:00PM EST Wednesday, CTXR came to a close right above 4 key technical chart levels in its: 5-Day Simple Moving Average (SMA) 20-Day SMA 5-Day Exponential Moving Average (EMA) 13-Day EMA Should support strengthen at those levels, could it act as a springboard for CTXR to revisit its former highs? #5. An Analyst Target Suggests Triple-Digit Potential Upside. According to reporting from Benzinga and TipRanks, D. Boral Capital analyst Jason Kolbert has set a $6 target on CTXR. From Wednesday's closing valuation, this target suggests over 600% upside potential. Could this suggest that CTXR is undervalued from current chart levels? ----- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has taken over our the top spot. Keep your eyes peeled for updates. Talk again shortly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 03/04/2026 and ending on 03/05/2026 to publicly disseminate information about (CTXR:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC eight thousand seven hundred fifty USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid thirty three thousand seven hundred fifty USD ("Funds"). These Funds were part of the fifty five thousand USD funds that TD Media LLC received from a third party named Sica Media LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (CTXR:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ctxr-c7pxt/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice